Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal CancerMarc Peeters, Jennifer Gansert, Thierry André et al.|Journal of Clinical Oncology|2010Cited by 1k
Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancerMarc Peeters, R. Sidhu, Timothy Price et al.|Annals of Oncology|2013Cited by 220
KRAS/NRAS and BRAF Mutations in the 20050181 Study of Panitumumab + FOLFIRI for the 2ND-Line Treatment of Metastatic Colorectal Cancer: Updated AnalysisMarc Peeters, Scott D. Patterson, Kelly S. Oliner et al.|Annals of Oncology|2014Cited by 3